CRENESSITY
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

CRENESSITY Trademark

Serial Number: 99025787

CRENESSITY is a trademark filed by Neurocrine Biosciences, Inc. on January 31, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Neurocrine Biosciences, Inc. (237 trademarks)

6027 Edgewood Bend Court
San Diego, CA 92130

Entity Type: 03

Trademark Details

Filing Date

January 31, 2025

Registration Date

Not Registered

Published for Opposition

December 2, 2025

Goods & Services

Providing medical information; providing medical information to patients, medical professionals in the field of other endocrine diseases and disorders; providing medical information to insurance companies in the field of congenital adrenal hyperplasia and other endocrine diseases and disorders; on-line information services, namely, providing medical information to patients, medical professionals in the field of other endocrine diseases and disorders; on-line information services, namely, providing medical information to insurance companies in the field of congenital adrenal hyperplasia and other endocrine diseases and disorders

Providing medical research information; providing medical research information in the field of pharmaceuticals and clinical trials focusing on other endocrine diseases and disorders; Scientific research in the nature of conducting clinical trials for pharmaceutical preparations for the treatment of congenital adrenal hyperplasia and other endocrine diseases and disorders, for others; conducting post-authorization pharmaceutical research for the marketing of pharmaceutical preparations and evaluating epidemiological results

Pharmaceutical preparations for the treatment of adrenal insufficiency; pharmaceutical preparations for the treatment of hormonal and genetic diseases, disorders and conditions; pharmaceutical preparations for the diagnosis, prevention and treatment of endocrine diseases and disorders; pharmaceutical preparations for the treatment of congenital adrenal hyperplasia; pharmaceuticals for the treatment of rare and orphan hormonal and genetic diseases, disorders and conditions

Filing History

SOU TEAS EXTENSION RECEIVED
Jun 16, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 27, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 2, 2025 NPUB
PUBLISHED FOR OPPOSITION
Dec 2, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 26, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 3, 2025 CNSA
DIVISIONAL PROCESSING COMPLETE
Oct 29, 2025 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 28, 2025 AITU
ASSIGNED TO LIE
Aug 27, 2025 ALIE
DIVISIONAL REQUEST RECEIVED
Aug 18, 2025 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Aug 18, 2025 ERTD
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 18, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 18, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 18, 2025 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Jun 9, 2025 GPRN
PRIORITY ACTION E-MAILED
Jun 9, 2025 GPRA
PRIORITY ACTION WRITTEN
Jun 9, 2025 CPRA
ASSIGNED TO EXAMINER
Jun 4, 2025 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
May 22, 2025 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 22, 2025 NWOS
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 20, 2025 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 20, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 20, 2025 COAR
APPLICATION FILING RECEIPT MAILED
Jan 31, 2025 MAFR
NEW APPLICATION ENTERED
Jan 31, 2025 NWAP